Cancer name Bladder Cancer
Cancer Type BLCA
Immunotherapy type Cancer Vaccine
Treatment BCG vaccine
Drugstatus Investigational
Drugbank ID DB12768
Checkpoints NA
Signature Type Protein
Signature TRAIL
Official Symbol TNFSF10
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental NA
Description The inflammatory response generated by this process leads to the release of cytokines and tumour necrosis factor related apoptosis-inducing ligand (TRAIL; also known as TNFSF10), which causes recruitment of granulocytes, macrophages, natural killer cells, and lymphocytes and results in the direct cell-mediated killing of the antigen-presenting cells. Another cytokine that has been evaluated in response to BCG is TRAIL, a member of the TNF family that is expressed by various immune cells, including cytotoxic lymphocytes, NK cells, and neutrophils.
PMID 29133939
Title Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy